In the phase III EV-301 trial, enfortumab vedotin (EV) has been shown to increase overall survival compared with chemotherapy in patients with metastatic urothelial carcinoma who had previously received chemotherapy and experienced disease progression after treatment with PD1 or PDL1 inhibitors. In a study published in European Urology, patient-reported outcome (PRO) analysis of health-related quality of life (HRQoL) was assessed in these patients. Specifically, changes in the validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) from baseline to week 12 were assessed. HRQoL was maintained with EV, with the most significant improvement observed in pain reduction (P = 0.027). Results from responder analyses showed that more patients in the EV than in the chemotherapy arm reported an improvement in most of the QLQ-C30 symptom scales (10 of 15). Although the authors acknowledged some limitations of this study, including declining completion rates owing to patient death, these PRO data support the safety and efficacy outcomes in the EV-301 trial and can be used in clinical practice to complement shared decision-making.